Treatment for ischemic stroke

ABSTRACT

Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patentapplication Ser. No. 14/731,783 filed on Jun. 5, 2015, which is acontinuation application of U.S. patent application Ser. No. 13/853,183filed on Mar. 29, 2013 (now U.S. Pat. No. 9,050,305), which claimspriority from U.S. provisional patent application No. 61/617,276 filedon Mar. 29, 2012.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

Not applicable.

FIELD OF THE INVENTION

The invention relates generally to the fields of neurology,pharmaceuticals, and medicine. More particularly, the invention relatesto the use of agents to protect brain tissue from ischemia/reperfusioninjury.

BACKGROUND

Stroke is the leading cause of disability and the third leading cause ofdeath in the USA. Much progress has been made regarding the mechanism ofbrain injury induced by ischemia/hypoxia, a major pathophysiology ofstroke. It is generally believed that excitotoxicity caused by excessiverelease of excitatory neurotransmitter glutamate plays an important rolein ischemia/reperfusion induced neuronal death. Despite extensiveresearch to develop medicines for stroke based on the known mechanismseither as glutamate receptor antagonists, Ca2+ channel blockers, enzymeinhibitors, inhibitors of apoptotic pathways, or ROS scavengers, etc.,these efforts have been disappointing. Part of the reason for thedisappointing results is due to the fact that the underpinning mechanismof stroke-induced neuronal injury is multi-factorial and hence it needsa therapeutic intervention that addresses the multi-factorial nature ofthe disease.

SUMMARY

It has been discovered that S-methyl-N, N-diethylthiolcarbamatesulfoxide (DETC-MeSO) is effective at protecting brain tissue exposed toa cerebral ischemia/reperfusion injury, and for minimizing the size ofinfarcts that develop as a result of the injury. It was also discoveredthat sulindac administration can protect brain tissue exposed to such aninjury, and minize the size of infarcts that develop as a result of theinjury. Also discovered was that the combination of granulocytecolony-stimulating factor (G-CSF; a stem cell enhancer and facilitator),DETC-MeSO, and sulindac can minimize the size of an infarct resultingfrom cerebral ischemia/reperfusion injury—even when each agent isadministered at doses much lower (e.g., 10× lower) than required toobserve a similar response using only one of the agents. This work alsoresulted in new information related to the molecular mechanisms by whichthese different agents can protect brain tissue exposed toischemia/reperfusion.

These discoveries led to the development of a method for minimizing thesize of a brain infarct which develops (or reducing the amount of braintissue damaged) in a mammalian subject as a consequence of a cerebralischemia/reperfusion injury. This method can include the step ofadministering to the subject at least one (e.g., 1, 2, or 3) of aDETC-MeSO agent, a G-CSF agent, and a sulindac agent, wherein the amountof the agent administered is effective for minimizing the size of abrain infarct that develops in a mammalian subject as a consequence ofthe cerebral ischemia/reperfusion injury. In this method, the subjectcan be who has been diagnosed with ischemic stroke prior to theadministration step and/or one that has been administered tissueplasminogen activator or another thrombolytic. Combinations of two ofDETC-MeSO agent, a G-CSF agent, and a sulindac agent might also beadministered (e.g., a DETC-MeSO agent and a sulindac agent, a DETC-MeSOagent and a G-CSF agent, or a G-CSF agent and a sulindac agent), or allthree can be administered. The at least one active ingredient can beincluded within a pharmaceutical composition formulated for injection,can be administered to the subject within 24 hours of the onset ofsymptoms of ischemic stroke, can be repeatedly administered to thesubject at least once per day for at least 3 or at least 7 days or untilthe infarcted lesion becomes at least 50% fibrotic.

Unless otherwise defined, all technical terms used herein have the samemeaning as commonly understood by one of ordinary skill in the art towhich this invention belongs. Although methods and materials similar orequivalent to those described herein can be used in the practice ortesting of the present invention, suitable methods and materials aredescribed below. All publications, patents, and patent applicationsmentioned herein are incorporated by reference in their entirety. In thecase of conflict, the present specification, including definitions willcontrol. In addition, the particular embodiments discussed below areillustrative only and not intended to be limiting.

DETAILED DESCRIPTION

The invention provides methods and compositions for treating stroke,protecting brain tissue, and minimizing the size of a brain infarctcaused by ischemia/reperfusion injury in a mammalian subject. The belowdescribed embodiments illustrate representative examples of thesemethods and compositions. Nonetheless, from the description of theseembodiments, other aspects of the invention can be made and/or practicedbased on the description provided below.

General Methods

Methods involving conventional organic chemistry, medicinal chemistry,pharmaceutical sciences, and drug development techniques are describedherein. Such methods are described in: Remington: The Science andPractice of Pharmacy, Lippincott Williams & Wilkins, 21st edition(2005); Drug Discovery and Development, Mukund S. Chorghade (Editor)Wiley-Interscience; 1st edition (2007); The Practice of MedicinalChemistry, 3rd Edition, Camille Georges Wermuth (Editor) Academic Press;3rd edition (2008); and Clayden et al., Organic Chemistry, OxfordUniversity Press, 1st edition (2000). Method in neurology are describedin Bradley's Neurology in Clinical Practice, 6th Edition, Elsevier(2012).

Methods of Treating Ischemic Stroke

Methods of treating ischemic stroke and other ischemic neurologicinjuries, or minimizing the size of a brain infarct caused byischemia/reperfusion injury in a mammalian subject can include the stepof administering one or more (e.g., 1, 2, or 3) of DETC-MeSO, G-CSF, andsulindac to the subject in an effective amount or amounts to minimizethe size of a brain infarct resulting from the injury. Effectivederivatives and analogues DETC-MeSO, G-CSF, and sulindac (includingsalts, epimers, and structurally related compounds of DETC-MeSO, G-CSF,and sulindac) might also be used in such methods. The G-CSF can berecombinant human G-CSF, or effective mutants, truncations,modifications (e.g., pegylated forms) thereof. The effectiveness of suchderivatives and analogues can be confirmed by the methods describedherein. Examples of such derivatives and analogues are described in U.S.Pat. Nos.: 3,654,349; 6,156,794; 7,414,139; 7,790,174 (and the relevantpatent references cited therein); 8,044,048; and U.S. patent applicationSer. No. 11/917,321. Each of the foregoing agents can be formulated as aseparate pharmaceutical composition, or combinations of 2 or more (e.g.,2 or 3) of the foregoing agents can be formulated as a separatepharmaceutical composition.

The subject can be a mammal such as a human being, a rodent, a cat, adog, a horse, a sheep, or a pig having or at risk for developingischemic stroke or a brain infarct (e.g., a subject experiencing one ormore transient ischemic attacks). As a non-limiting example, the subjectcan be a human being diagnosed with cerebral vessel occlusion or onehaving transient ischemic attacks. The subject can also be a human beingwho has been administered tissue plasminogen activator (e.g., followingbeing diagnosed with acute cerebral vessel occlusion). The initial doseof one or more of DETC-MeSO, G-CSF, sulindac, or derivatives oranalogues thereof can be administered within 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 36, or 48 h of the onsetof symptoms of ischemic stroke. For a subject at high risk fordeveloping an ischemic stroke (e.g., subject experiencing transientischemic attacks or having a thrombosis), the one or more of DETC-MeSO,G-CSF, sulindac, or derivatives or analogues thereof can be administeredprophylactically, with a frequency of four times per day, thrice perday, twice per day, once a day, or once every 2, 3, 4, 5, 6, 7, or 14days until the risk is decreased (e.g., transient ischemic attacks stopor the thrombosis is cleared).

The pharmaceutical formulation can be administered to the subject by anysuitable method including orally, topically, by injection (e.g.,intravenous, subcutaneous, intraperitoneal, or intrathecal injection;injection into an IV bag in fluid communication with a blood vessel inthe subject; and infusion such as through a catheter), or implanting aslow-release depot device. For oral formulations, administrations canbe, without limitation, four times per day, thrice per day, twice perday, once a day, or once every 2, 3, 4, 5, 6, 7, 14, 28, 35, 42, or 49days (or until the ischemia/reperfusion-induced lesion becomes at least50, 60, 70, 80, 90, or 100% fibrotic or acellular). For injectableformulations, administrations can be, without limitation, 100 μl to 100ml (e.g., 100 μl, 500 μl, 1 ml, 2 ml, 3, ml, 4 ml, 5 ml, 10, ml, 20 ml,50 ml, or 100 ml) four times per day, thrice per day, twice per day,once a day; or once every 2, 3, 4, 5, 6, 7, 14, 28, 35, 42, or 49 days(or until the ischemia/reperfusion-induced lesion becomes at least 50,60, 70, 80, 90, or 100% fibrotic or acellular). Other possible methodsof administration include intra-nasal (e.g., via a liquid spray, such asvia a plastic bottle atomizer), inhalation or insufflation (e.g., of adry powder formulation), and mucosal (rectal, vaginal, or buccal).Administration can continue indefinitely or until the infarct iscompletely formed or the factors causing an elevate risk for developingan ischemic stroke are removed. Brain lesions/infarcts can be monitoredby methods known in the art, e.g., CT scanning.

The effective amount of the one or more of DETC-MeSO, G-CSF, sulindac,or derivatives or analogues thereof may be delivered in multiple doses,preferably within about three hours of the sudden onset of neurologicalsymptoms associated with stroke. The effective amount of the one or moreof DETC-MeSO, G-CSF, sulindac, or derivatives and analogues thereof maybe delivered in combination with ongoing administration of aspirin toreduce the risk of blood clot formation, or administration of otheragents to improve blood flow by reducing the formation of clots ordissolving blood clots (e.g., estrogen, eNOS inducer, L-arginine, astatin, aspirin, tissue plasminogen activator, modified viper venom, andprourokinase). In addition, agents and devices for controlling andregulating blood flow may also be used in combination with the one ormore of DETC-MeSO, G-CSF, sulindac, or derivatives or analogues thereofto treat stroke or stroke-like events.

Pharmaceutical Formulations

The one or more active agents described herein can be included alongwith one or more pharmaceutically acceptable carriers or excipients tomake pharmaceutical compositions which can be administered to thesubject. Suitable formulations for use in the present invention aredescribed in Remington's Pharmaceutical Sciences, Mace PublishingCompany, Philadelphia, Pa., 17th ed. (1985) and updates thereto.

In pharmaceutical compositions including sulindac or derivatives oranalogues of sulindac (“sulindac agents”), the sulindac agent can beincluded as at least 0.001% (e.g., at least 0.001, 0.002, 0.003, 0.004,0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06,0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1,1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0%) by weight of theformulation. Preferably the composition comprises between 0.001 to 3%,0.005 to 2%, or 0.005 to 1.5% sulindac agent by weight. The dose of thesulindac agent per administration can be in the range of 0.01 to 5mg/kg.

In pharmaceutical compositions including DETC-MeSO or derivatives oranalogues of DETC-MeSO (“DETC-MeSO agents”), the DETC-MeSO agent can beincluded as at least 0.01% (e.g., at least 0.01, 0.02, 0.03, 0.04, 0.05,0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8,9, or 10%) by weight of the formulation. The dose of the DETC-MeSO agentagent per administration can be in the range of 0.2 to 20 mg/kg(preferably 1-10 mg/kg).

In pharmaceutical compositions including G-CSF or derivatives oranalogues of G-CSF (“G-CSF agents”), the G-CSF agent can be included asat least 0.01% (e.g., at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07,0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2,1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, or 5%) by weight of theformulation. The dose of the DETC-MeSO agent per administration can bein the range of 2 to 500 μg/kg (preferably 10 to 100 μg/kg).

The pharmaceutical composition(s) might also be formulated for injectionand administered by injection. Such compositions can have a pH ofbetween 6.5 and 8.5 or between 6.8 and 7.8. Excipients/carriers/otheringredients can include a sterile aqueous buffer, an isotonizing agent,a microbicidal agent or preservative, a chelating agent, a solubilityenhancing agent such as dimethylsulfoxide, and/or other ingredients. Theisotonizing agent can be, e.g., sorbitol, glycerine, polyethyleneglycol, propylene glycol, glucose and sodium chloride. The microbicidalagent/preservative can be, e.g., para-oxybenzoic acid esters, benzylalcohol, para-chloro-meta-xylenol, chlorocresol, phenetyl alcohol,sorbic acid and salts thereof, thimerosal, chlorobutanol, etc. Thechelating agent can be, for example, sodium edetate, sodium citrate orthe sodium salt of condensed phosphoric acid.

The pharmaceutical composition can also be included in an implantableslow-release depot device that can be placed in the subject (e.g., at asubcutaneous position) by surgical techniques. In such devices, the oneor more of DETC-MeSO, G-CSF, sulindac, or derivatives and analoguesthereof can be manufactured into microparticles (e.g., with a particlesize of 1 to 200 microns) which are embedded in a biocompatiblepharmacologically acceptable polymer or a lipid encapsulating agent. Thedepot formulations can be designed to release all or substantially allthe active material over an extended period of time, e.g. several weeksup to 6 months. The matrix, e.g. polymer or lipid matrix, if present, isadapted to degrade sufficiently to be transported from the site ofadministration within one to 6 months after release of all orsubstantially all the active agent.

To enhance half-life, the one or more of DETC-MeSO, G-CSF, sulindac, orderivatives and analogues thereof may be encapsulated, introduced intothe lumen of liposomes, prepared as a colloid. A variety of methods areavailable for preparing liposomes, as described in, e.g., Szoka, et al.,U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028 each of which isincorporated herein by reference. The one or more of DETC-MeSO, G-CSF,sulindac, or derivatives and analogues thereof may also be formulatedfor parenteral administration and presented in unit dosage form inampules, prefilled syringes, small volume infusion containers ormulti-dose containers with an added preservative.

EXAMPLES Example 1 Stroke Model

Because most human focal ischemic strokes occur as a result of blockageof the middle cerebral artery, a proximal middle cerebral arteryocclusion (MCAO) model was developed to evaluate the agents describedherein. In the model, adult male Sprague-Dawley rats (250-300 g) aresubjected to MCAO by inserting a filament and advancing 18-22 mm fromthe carotid artery bifurcation into the internal carotid artery.Reperfusion is accomplished by withdrawing the filament 2 h after MCAO.Cerebral blood flow (CBF) is measured during surgery until 30 min afterreperfusion using the Laser Doppler flow (LDF) meter. In this procedure,LDF showed a marked reduction in CBF. The infarcts that formed wereanalyzed by triphenyltetrazolium chloride (TTC) staining of the brain.

Example 2 Effect of DETC-meSO Treatment on Stroke-Induced BrainInfarction.

DETC-MeSO at 1-7 mg was given two times: 1st injection given 1 hr beforeMCAO surgery and 2nd injection given on day 11. The animals weresacrificed on 11th day after ischemia induction. The brain was stainedwith 1% TTC. DETC-MeSO-treated animlas exhhited significantly reducedbrain infarct size compared to the control group. In a secondexperiment, a quantitative analysis of infarct size with and withoutDETC-MeSO treatment was performed. For evaluation of the effects ofDETC-MeSO animals were given 2 injections of the drug, one at 60 minutesbefore ischemia and one at 20 minutes before the start of reperfusion.After ischemia and reperfusion animals were sacrificed for determinationof infarct size by TTC staining. Animals treated with DETC-MeSOdemonstrated a decrease in infarct size to 29% the area of the infarctsin the no-drug control group.

Example 3 Effect of DETC-MeSO on Expression of C/EBP Homologues Protein(CHOP) in Primary Neuronal Cultures Subjected to Hypoxia andReoxygenation.

Primary neuronal cultures were subjected to 24 hours of hypoxia followedby 16 hours of reoxygenation and cells were harvested for proteinextraction and Western blot analysis for expression of CHOP. Levels ofCHOP were quantified by densitometry and expressed as a percentage ofthe signal for actin control samples. Cells subjected to hypoxiademonstrated about double the of CHOP expression compared to bothcontrol cells (not subjected to hypoxia) and DETC-MeSO-treated cellssubjected to hypoxia.

Example 4 Effect of DETC-MeSO on Expression of P-IRE-1 in PrimaryNeuronal Cultures Subjected to Hypoxia and Reoxygenation.

Primary neuronal cultures were subjected to 24 hours of hypoxia followedby 16 hours of reoxygenation and cells were harvested for proteinextraction and Western blot analysis for expression of P-IRE-1. Levelsof P-IRE-1 were quantified by densitometry and expressed as a percentageof the signal for actin control samples. Cells subjected to hypoxiademonstrated about 4-5 times the amount of P-IRE-1 expression comparedto control cells (not subjected to hypoxia) and about 3-3.5 times theamount of P-IRE-1 expression compared to DETC-MeSO-treated cellssubjected to hypoxia.

Example 5 Effect of a Combination of G-CSF/DETC-MeSO/Sulindac onStroke-Induced Brain Infarction.

A combination of G-CSF/DETC-MeSO/sulindac at dose of G-CSF, 25 ug/kg;DETC-MeSO, 0.52 mg/kg; and sulindac, 1 mg/kg; was administered toanimals 24 hrs post middle cerebral artery occlusion (MCAO) surgery inrat stroke model. Infarct size was reduced by approximately 40% comparedto control animals (data from 14 experiments), when examined 8 daysafter MCAO surgery. Furthermore, ischemia-induced pro-apoptotic proteins(e.g., Bax and Bak) or ER stress proteins (e.g., GRP78) were reducedmarkedly at the infarct area to an extent of 55%, 88% and 62%,respectively in the animals receiving G-CSF/DETC-MeSO/sulindac comparedto no-treatment controls. In addition, the anti-apoptotic protein Bc12increased greatly (437% at the core and 225% at the penumbra) in theanimals receiving G-CSF/DETC-MeSO/sulindac compared to no-treatmentcontrols.

Example 6 Effect of Sulindac on Stroke-Induced Brain Infarction.

Sulindac at 0.2 mg/kg reduced the brain infarct size when it wasadministered either before or post the middle cerebral artery occlusion(MCAO) surgery in the animal model described in Example 1. Specifically,animals with sham-operated or MCAO operated with or without sulindactreatment were sacrificed 3 and 11 days after stroke onset, and infarctsize in the left hemisphere was measured by 2, 3, 5-triphenyltetrazoliumchloride (TTC) staining. Western blotting on the core and the penumbratissue of both hemispheres was employed for analysis of the expressionof key proteins involved in apoptosis (Bcl-2), and cell protection andsurvival e.g., two heat shock proteins (HSP27, HSP70) and AKT. TTCanalysis of brain slices indicated a decrease in infarct size insulindac treated animals at 4 mm, 6 mm and 8 mm from the anterior pole.The Western blotting results indicated that Hsp 27 protein expression inischemic penumbra and core on Day 3 and 11 was significantly increasedin the sulindac-treated animals compared to the control non-treatedanimals. There were also significant increases in the protectivemolecules Akt and Bcl-2 in ischemic penumbra and core in thesulindac-treated animals compared to the control non-treated animals.

Example 7 DETC-MeSO as a Therapeutic Agent for Stroke Treatment.

DETC-MeSO is effective in reducing stroke-induced brain infarctionadministered either before or post to ischemic condition in the MCAOmodel described in Example 1. DETC-MeSO at 5.6 mg/kg was given one hourbefore MCAO surgery and reperfusion and then continued at the same dosefor 4 days. The animals were sacrificed on 4th day after ischemiainduction. The brain was stained with 1% TTC. DETC-MeSO significantlyreduced brain infarct size at the dose specified. Quantitative analysisof infarct size with and without DETC-MeSO treatment was performed.After ischemia and reperfusion, the animals were sacrificed fordetermination of infarct size by TTC staining. Animals treated withDETC-MeSO demonstrated a decrease in infarct size by 50% at 6 mm fromfrontal pole compared with the area of the no-drug treated group. Alldata were expressed as the mean ±SEM (N=21). One-way ANOVA with post-hocDunnett test was used to compare means between groups. Differences ofP<0.05 were considered statistically significant.

Example 8 Effect of DETC-MeSO Treatment Prior to MCAO Surgery andReperfusion on the Expression of Bcl-2 and Hsp27 Proteins in the MCAOStroke Animal Model.

Both Bcl-2 and Hsp-27 were found to be significantly increased in boththe core and the penumbra region of the infarct brain tissue in the MCAOanimals treated with DETC-MeSO compared to non-treated control animals.Western blots were quantified by densitometric analyses expressed asarbitrary unit. All data were expressed as the mean±SEM (N=8). Two-wayANOVA with post-hoc Bonferroni test (Prism software) was used to comparemeans between groups on core and penumbra with or without administrationof DETC-MeSO. Differences of P<0.05 were considered statisticallysignificant.

Example 9 Effect of DETC-MeSO Treatment Post MCAO Surgery.

DETC-MeSO at 5.6 mg/kg was given by intraperitoneal injection 24 hr postMCAO surgery/reperfusion and by continued daily injection at the samedose for additional 4 and 8 days until the animals were sacrificed.Morphological observation based on TTC staining shows that DETC-MeSOsignificantly reduced brain infarct size when it was administered 24 hrspost MCAO/reperfusion at the dose specified in both 4 and 8 days.Statistical analysis of the results obtained from 8 animals showed thatDETC-MeSO treatment post MCAO surgery/reperfusion reducedischemia—induced brain infarct size by 64+/−11% and 61+/−7% at 4- and8-days respectively. The size of infarction of the DETC-MeSO-treatedgroup was calculated as % of infarct area from the non-DETC-MeSO-treatedgroup.

Example 10 G-CSF as an Effective Therapeutic Agent for Treatment ofStroke.

In the animal model described in Example 1, G-CSF administered 24 hourspost ischemia at 50 μg/kg greatly reduced the ischemia-induced braininfarct size compared to non-treated control animals. The gross anatomyof brain sections (2 mm) was examined after TTC stain. Infarct volumewas measured in brain slices at a distance of 2 mm interval from thefrontal pole. Infarct volume and the percentage of infarct volume inentire brain was significantly reduced in G-CSF treated animals (n=5)versus the control group (n=5). (C) Percentage of infarct volume inentire brain of G-CSF treated animals (n=5) versus control group (n=5)(significance of P<0.05). Furthermore, it was demonstrated that theneuroprotective function of G-CSF is partially due to its up-regulationof endoplasmic reticular (ER) pro-survival/anti-apoptotic markerproteins (e.g., pAKT; JNK; and Bcl-2) or down-regulation ofpro-apoptotic proteins (e.g., CHOP) by Western blotting as describedabove.

Example 11 Sulindac as a Therapeutic Agent for Stroke.

Sulindac administered via subcutaneous injection (0.2 mg/day) for 2 daysbefore (Pre-MCAO Surgery/Reperfusion) and 24 hrs after ischemia (PostMCAO surgery/Reperfusion) in the animal described in Example 1,significantly reduced the infarct size induced by stroke compared tocontrol non-treated animals. Quantitative analysis of TTC stained brainslices indicated a significant decrease in infarct size in sulindactreated animals at 4 mm, 6 mm, 8 mm and 10 mm from the anterior pole(P<0.01; 2 way ANOVA). In addition, the level of anti-apoptotic proteinmarkers such as Bcl-2 was greatly elevated in sulindac-treated groupcompared to control non-treated animals.

Example 12 G-CSF/DETC-MeSO/Sulindac Combined Multi-drug Treatment forStroke.

In the animal described in Example 1, it was found thatG-CSF/DETC-MeSO/sulindac at dose of 1/10 of the individual drug (G-CSF,10 ug/kg; DETC-MeSO, 0.56 mg/kg and sulindac, 0.2 mg/kg), reduced theinfarct size significantly, approximately, 40%, when it was administered24 hrs post MCAO surgery/reperfusion and examined at 8 days afterMCAO/Reperfusion while individual drug at such a low concentrationshowed no significant effect on ischemia-induced infarct size. In asimilar experiment, G-CSF/DETC-MeSO/sulindac at low dose ( 1/10 of theoriginal individual drug used) (G-CSF, 10 ug/kg; DETC-MeSO, 0.56 mg/kgand sulindac, 0.2 mg/kg), reduced the infarct size significantly,approximately, 70%, when it was administered 24 hrs post MCAO surgeryand examined at 4 days after MCAO/Reperfusion. Data represented infarctvolume as percent (%) of the total ipsilateral hemisphere volume and aremeans ±SD of 9 experiments for MCAO and MCAO plusDETC-MeSO/GCSF/Sulindac combined multi-drug treatment.

Example 13 Experiment 2: Effect of G-CSF/DETC-MeSO/Sulindac Multi-drugTreatment Post MCAO on the Expression of ER Stress Proteins andPro-apoptotic and Anti-apoptotic Proteins.

Ischemia-induced pro-apoptotic proteins (e.g., Bax, Bak) or ER stressproteins (e.g., GRP78) were reduced markedly at the infarct area to anextent of 55%, 88% and 62%, respectively, in animals administeredG-CSF/DETC-MeSO/sulindac as described in Example 12 compared to no drugcontrol animals. In addition, the anti-apoptotic proteins (e.g., Bcl-2)in both the infarct and penumbra regions was increased greatly to theextent of 437% and 225%, respectively. Western blots were quantified bydensitometric analyses expressed as fold increase using the ipsilateralunlesioned side as the control. All data were expressed as the mean±SEM(N=8). Two-way ANOVA with post-hoc Bonferroni test (Prism software) wasused to compare means between groups on core and penumbra with orwithout administration of G-CSF/DETC-MeSO/sulindac multi-drug treatment.Differences of P<0.05 were considered statistically significant.

Other Embodiments

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A method of treating a mammalian subject withacute cerebral vessel occlusion, the method comprising the step ofadministering to the subject a N-diethylthiocarbamate sulfoxide(DETC-MeSO) agent.
 2. The method of claim 1, wherein the DETC-MeSO agentis administered to the subject within 24 hours of the onset of symptomsof cerebral vessel occlusion.
 3. The method of claim 1, wherein theDETC-MeSO agent is repeatedly administered to the subject at least onceper day for at least 3 days.
 4. The method of claim 1, wherein theDETC-MeSO agent is repeatedly administered to the subject at least onceper day for at least 7 days.
 5. The method of claim 1, wherein thesubject has been administered tissue plasminogen activator.
 6. Themethod of claim 1, further comprising administering to the subject asulindac agent.
 7. The method of claim 1, further comprisingadministering to the subject a Granulocyte-colony stimulating factor(G-CSF) agent and a sulindac agent.
 8. A method of preventing braindamage caused by ischemic stroke in a mammalian subject experiencingtransient ischemic attacks, the method comprising the step ofadministering to the subject a N-diethylthiocarbamate sulfoxide(DETC-MeSO) agent.
 9. The method of claim 8, wherein the DETC-MeSO agentis repeatedly administered to the subject until the transient ischemicattacks stop.
 10. A method of preventing brain damage caused by ischemicstroke in a mammalian subject having a thrombosis, the method comprisingthe step of administering to the subject a N-diethylthiocarbamatesulfoxide (DETC-MeSO) agent.
 11. The method of claim 10, wherein theDETC-MeSO agent is repeatedly administered to the subject until thethrombosis is cleared.